The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised $110 million by offering 6.5 million shares at $17, the high end of the range of $15 to $17. NexImmune originally filed to sell 4.7 million shares, before increasing the...read more
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday.
The Gaithersburg, MD-based company now plans to raise $94 million by offering 5.9 million shares at a price range of...read more
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, announced terms for its IPO on Monday. The Gaithersburg, MD-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. Existing...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Immuno-oncology biotech NexImmune prices upsized IPO at $17 high end
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised $110 million by offering 6.5 million shares at $17, the high end of the range of $15 to $17. NexImmune originally filed to sell 4.7 million shares, before increasing the...read more
Immunotherapy biotech NexImmune ups share offering by 25% ahead of $94 million IPO
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Gaithersburg, MD-based company now plans to raise $94 million by offering 5.9 million shares at a price range of...read more
Immunotherapy biotech NexImmune sets terms for $75 million IPO
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, announced terms for its IPO on Monday. The Gaithersburg, MD-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. Existing...read more